Tag: Dexcom
In brief: Stakeholders push back, Owens & Minor upsizes offering, Merits expands
April 4, 2025HME News Staff
WASHINGTON – AAHomecare, the Council for Quality Respiratory Care and VGM are raising concerns with CMS and lawmakers about the access issues and the negative health outcomes that could result from a recent draft proposal for noninvasive positive pressure ventilation.
CMS on March 11 released a proposed decision in response to the request to reconsider NCD 280.1 to establish coverage policies for the use of noninvasive home mechanical ventilators and respiratory assist devices for...
Saskatchewan expands CGM coverage
April 3, 2025HME News Staff
BURNABY, B.C. – The government of Saskatchewan has expanded public coverage for continuous glucose monitoring (CGM) systems. The expansion, which now provides full coverage for CGMs for young adults ages 18 to 25 and seniors ages 65 and over, marks a significant step toward improving clinical outcomes and enhancing the quality of life for nearly 10,000 individuals living with diabetes in the province, Dexcom says. "Managing diabetes presents unique challenges for Canadians who rely on...
In brief: Aetna pauses CPAP change, FDA warns Dexcom, Owens & Minor launches offering
March 28, 2025HME News Staff
WASHINGTON – Aetna has put a proposed change on hold for review after AAHomecare asked the insurer to reconsider using certain adherence codes that can only be billed by clinicians not DME providers.
The proposed change, announced in January, stated: “Beginning April 1, 2025, we’ll no longer reimburse the CPAP device or the supplies unless adherence to positive airway pressure therapy is documented using adherence codes G8851, G8854 and G8855 on the claim.”
“On...
FDA issues warning to Dexcom
March 27, 2025HME News Staff
SAN DIEGO – Dexcom has received a warning letter from the U.S. Food and Drug Administration regarding “non-conformities” in manufacturing and quality processes after inspections of its facilities in Sad Diego and Mesa, Ariz. In a form 8-K filed with the U.S. Securities and Exchange Commission, the company said it takes the matters identified in the warning letter seriously, has already submitted several responses to Form 483 and is in the process of preparing a written response...
Dexcom appoints former Masimo exec as chief commercial officer
March 27, 2025HME News Staff
SAN DIEGO – Dexcom has named Jon Coleman as chief commercial officer to oversee the company’s global commercial organization, including sales, marketing and customer experience. “Jon has demonstrated the ability to lead organizations through the complexities of global health care with consistently strong performance across a variety of sectors and channels,” said Kevin Sayer, chairman, president and CEO at Dexcom. “This broad experience across market segments and regions...
‘Now is the time to push for greater investment in CGM tech,’ report finds
March 24, 2025HME News Staff
EDINBURGH, Scotland, and SAN DIEGO – Tech, not medicine, is the future of care for Type 2 diabetes patients, according to a new report from Dexcom.
Fifty-two percent of health care professionals ranked access to continuous glucose monitors and education as having the potential to positively help people with Type 2 manage their condition in the next 10 years compared with 30% who cited better or more effective medications.
“With policymakers increasingly focused on digital...
In brief: Medline’s IPO, GLP-1's expansion, DME’s ‘hidden cost,’ Nymbl’s investment
January 3, 2025HME News Staff
NORTHFIELD, Ill. – Medline has confidentially submitted a draft registration statement on Form S-1 to the U.S. Securities and Exchange Commission for a proposed initial public offering of its common stock.
The number of shares to be offered and the price range for the proposed offering have not yet been determined. The offering is subject to market and other conditions and the completion of the SEC's review process.
In 2021, Medline announced it had received outside...
Abbott, DexCom settle patent disputes
January 2, 2025HME News Staff
SAN DIEGO and ABBOTT PARK, Ill. – DexCom and Abbott Diabetes Care have entered into a settlement and patent cross license agreement to resolve all outstanding patent litigation between the parties related to their continuous glucose monitors, according to a Form 8-K filed by Dexcom with the U.S. Securities and Exchange Commission. Both companies have accused the other of infringing certain patents and each company has filed counterclaims and actions to invalidate the other’s patents....
Dexcom partners with, invests in, Ōura
November 21, 2024HME News Staff
SAN DIEGO & SAN FRANCISCO – Dexcom’s glucose data with be integrated with the Oura Ring’s vital sign, sleep, stress, heart health and activity data to provide users of both products with a more complete picture of overall health, the companies say. Dexcom is also making a $75 million strategic investment in Ōura’s Series D funding, putting the company’s valuation at more than $5 billion. “Dexcom offers the most accurate glucose biosensing systems on the market...
Tandem, Dexcom integration approved in Canada
August 1, 2024HME News Staff
MARKHAM, Ontario – Tandem Diabetes Care and Dexcom have announced the updated t:slim X2 insulin pump software is compatible with both Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems and is authorized for sale by Health Canada. This integration allows users of the t:slim X2 insulin pump with Control-IQ technology, to have even more choice in how they manage their diabetes. "This integration marks the first time an AID system in Canada is compatible with both Dexcom G7...